The DOI matches its Crossref record; 208 of the 209 references it cites were found in a registry or an index.
Metabolic origins and clinical significance of LDL heterogeneity
Open accessAbstract
LDLs in humans comprise multiple distinct subspecies that differ in their metabolic behavior and pathologic roles. Metabolic turnover studies suggest that this heterogeneity results from multiple pathways, including catabolism of different VLDL and IDL precursors, metabolic remodeling, and direct production. A common lipoprotein profile designated atherogenic lipoprotein phenotype is characterized by a predominance of small dense LDL particles. Multiple features of this phenotype, including increased levels of triglyceride rich lipoprotein remnants and IDLs, reduced levels of HDL and an association with insulin resistance, contribute to increased risk for coronary heart disease compared with individuals with a predominance of larger LDL. Increased atherogenic potential of small dense LDL is suggested by greater propensity for transport into the subendothelial space, increased binding to arterial proteoglycans, and susceptibility to oxidative modification. Large LDL particles also can be associated with increased coronary disease risk, particularly in the setting of normal or low triglyceride levels. Like small LDL, large LDL exhibits reduced LDL receptor affinity compared with intermediate sized LDL. Future delineation of the determinants of heterogeneity of LDL and other apoB-containing lipoproteins may contribute to improved identification and management of patients at high risk for atherosclerotic disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Notably, large, dense LDL-cholesterol particles are also associated with increased CVD risk, especially together with low TAG levels (18)”
From Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials (2016) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many studies further suggest that the smallest particles in the LDL fraction carry the greatest atherogenicity.84”
From Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement (2005) · cites this paper as [84]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“On the other hand, increased levels of LDL-cholesterol are clearly associated with increased risk of CVD (18,19)”
From Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials (2016) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“because particle size, in addition to lipoprotein cholesterol content, may help predict atherogenic risk, the net effect of algal DHA supplementation on serum lipoproteins and lipids may be beneficial despite the increase in LDL-C (55).”
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the associated alteration of the LDL-cholesterol phenotype from small dense LDL to greater LDL has been associated with reduced atherogenicity (18,19)”
From Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials (2016) · cites this paper as [18]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Low-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780 · cited 3×
“In most, but not all (180) of these studies, the disease risk associated with small dense LDL was no longer significant after adjusting for covariates, including triglycerides (136, 181) or other risk factors (133).”
BackgroundResultAtherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk
Austin, M. A., King, M. C., Vranizan, K. M., & Krauss, R. M. (1990) · Circulation · doi:10.1161/01.cir.82.2.495 · Cited by 1,411 · cited 2×
“LDL subclass pattern B, is 30–35% in adult men, but is much lower (5–10%) in males 20 years and in premenopausal women (131, 133), and is intermediate (15–25%)”
BackgroundMethodSelf-citationManninen, V, Tenkanen, L., Koskinen, P., Huttunen, J. K., Mänttäri, M., Heinonen, O. P., & Frick, M. H. (1992) · Circulation · doi:10.1161/01.cir.85.1.37 · Cited by 1,329
Stampfer, M. J. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110036029 · Cited by 1,079 · cited 9×
“Coronary atherosclerosis progression in a more recent study (196) was most strongly correlated with change in cholesterol levels in VLDL remnants and IDL, with much weaker relationship for cholesterol and apoB in LDL. Finally, in patients with coronary artery disease participating in the Monitored Atherosclerosis Regr…”
BackgroundInfluentialLamarche, B., Tchernof, A., Moorjani, S., Cantin, B., Dagenais, G. R., Lupien, P. J., & Despre´s, J.-P. (1997) · Circulation · doi:10.1161/01.cir.95.1.69 · Cited by 1,077
Identification of multiple subclasses of plasma low density lipoproteins in normal humans.
Krauss, R. M., & Burke, D. J. (1982) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38178-5 · Cited by 992
Self-citationAn Apolipoprotein Influencing Triglycerides in Humans and Mice Revealed by Comparative Sequencing
Pennacchio, L. A., Olivier, M., Hubacek, J. A., Cohen, J. C., Cox, D. R., Fruchart, J.-C., Krauss, R. M., & Rubin, E. M. (2001) · Science · doi:10.1126/science.1064852 · Cited by 921 · cited 1×
“A subset of 501 subjects in this population is described in reference (211).”
BackgroundSelf-citationGardner, C. D. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540110029028 · Cited by 843 · cited 2×
“Prospective studies of the relation of peak LDL particle size to the development of coronary artery disease have been carried out using nested case-control analysis in the Physician's Health Study (182), the population based Stanford Five Cities Project (183), and the Quebec Cardiovascular Study (184–186).”
Backgroundde Graaf, J., Hak-Lemmers, H. L., Hectors, M. P., Demacker, P. N., Hendriks, J. C., & Stalenhoef, A. F. (1991) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.11.2.298 · Cited by 714
Reaven, G. M., Chen, Y. D., Jeppesen, J., Maheux, P., & Krauss, R. M. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116541 · Cited by 690 · cited 2×
“On the basis of the strength of the relationship between insulin resistance and the pattern B, small dense LDL has been added to the list of abnormalities that characterize the “metabolic syndrome” (158).”
BackgroundSelf-citation
Research works printed but not linked: 9
- Alaupovic, 1992, The lipoprotein family concept and its clinical significance, Nutr. Metab. Cardiovasc. Dis., 2, 52
- Gofman, 1954, The serum lipoprotein transport system in health, metabolic disorders, atherosclerosis and coronary artery disease, Plasma., 2, 413
- Krauss, 1995, Altered metabolism of large low density lipoproteins in subjects with predominance of small low density lipoproteins, Circulation., 92, I
- Blanche, 1999, Absence of hepatic lipase results in reduction of human-like small dense LDL in Fat-Fed human apoB Transgenic mice, Circulation., 100, A-13
- Blanche, 1995, Similar low density lipoprotein subclasses in fat-fed human-apoB transgenic mice and humans, Circulation., 92, I
- Olin, 1999, Apo CIII modulates lipoprotein binding to Vascular Proteoglycans, Circulation., 100, 3658
- Bu, 1992, Major gene control of atherogenic lipoprotein phenotype (ALP): a quantitative segregation analysis in 20 coronary artery disease (CAD) pedigrees, Am. J. Hum. Genet., 51, A336
- Miller, 1993, Baseline-triglyceride levels predict angiographic benefit of colestipol plus niacin therapy in the cholesterol-lowering atherosclerosis study (CLAS), Circulation., 4, I
- Miller, 1994, Predominance of mid-density low density lipoproteins predicts angiographic benefit of lovastatin in the monitored atherosclerosis regression study, Circulation., 90, I460
Cited by
Grundy, S. M., Cleeman, J. I., Daniels, S. R., Donato, K. A., Eckel, R. H., Franklin, B. A., Gordon, D. J., Krauss, R. M., Savage, P. J., Smith, S. C., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.169404 · Cited by 11,961
Self-citationNordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Jung, U., & Choi, M.-S. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15046184 · Cited by 1,880
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Self-citationBorén, J., Chapman, M. J., Krauss, R. M., Packard, C. J., Bentzon, J. F., Binder, C. J., Daemen, M. J., Demer, L. L., Hegele, R. A., Nicholls, S. J., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz962 · Cited by 1,601
“be influenced by the proteome, lipidome, proteoglycan binding, aggregability, and oxidative susceptibility.(64,96,97) The atherogenic”
BackgroundSelf-citation
Metadata
- Authors
- Berneis, K. K., & Krauss, R. M.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Corresponding author
- Krauss, Ronald M.
- ORCID
- Krauss, Ronald M.
- Venue
- Journal of Lipid Research
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 43
- Issue
- 9
- Pages
- 1363-1379
- ISSN
- 0022-2275 (ISSN-L)
- OpenAlex
- W2009013500
- Cited by
- 896
- References
- 209
- Citations by year
- 2026: 26 · 2025: 38 · 2024: 27 · 2023: 32 · 2022: 47 · 2021: 42 · 2020: 28 · 2019: 40 · 2018: 35 · 2017: 47 · 2016: 43 · 2015: 43 · 2014: 46 · 2013: 38 · 2012: 44
- FWCI
- 4.43
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6574 d)
- Locations
- Journal of Lipid Research (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Institutes of Health (5p01hl018574-26)
- National Heart, Lung, and Blood Institute (HL-18574)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- small dense LDL, atherogenic lipoprotein phenotype, VLDL catabolism, IDL, HDL cholesterol, insulin resistance, coronary heart disease risk, oxidative modification, atherosclerosis, lipoprotein metabolism
- MeSH terms
- Coronary Artery Disease, Disease Susceptibility, Humans, Lipase, Lipoproteins, LDL, Phenotype
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Metabolic origins and clinical significance of LDL heterogeneity. https://app.cochat.ai/papers/10.1194/jlr.r200004-jlr200
- The paper
- Berneis, K. K., & Krauss, R. M. (2002). Metabolic origins and clinical significance of LDL heterogeneity. Journal of Lipid Research. https://doi.org/10.1194/jlr.r200004-jlr200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.